On Friday, Abbvie Inc (NYSE: ABBV) was -0.41% drop from the session before settling in for the closing price of $198.86. A 52-week range for ABBV has been $163.81 – $218.66.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -14.67% over the past five years. When this article was written, the company’s average yearly earnings per share was at 18.80%. With a float of $1.76 billion, this company’s outstanding shares have now reached $1.77 billion.
Let’s look at the performance matrix of the company that is accounted for 55000 employees. In terms of profitability, gross margin is 74.26%, operating margin of 20.46%, and the pretax margin is 5.19%.
Abbvie Inc (ABBV) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Abbvie Inc stocks. The insider ownership of Abbvie Inc is 0.09%, while institutional ownership is 75.10%. The most recent insider transaction that took place on Aug 01 ’25, was worth 12,043,268. Before that another transaction happened on Aug 05 ’25, when Company’s EVP, CHIEF BUS/STRAT OFFICER sold 13,295 for $198.51, making the entire transaction worth $2,639,253. This insider now owns 58,247 shares in total.
Abbvie Inc (ABBV) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted 3 earnings per share (EPS) during the time that was better than consensus figure (set at 2.92) by 0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of 3.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 18.80% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 16.04% during the next five years compared to -14.67% drop over the previous five years of trading.
Abbvie Inc (NYSE: ABBV) Trading Performance Indicators
You can see what Abbvie Inc (ABBV) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 0.61. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.00. Likewise, its price to free cash flow for the trailing twelve months is 19.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.10, a number that is poised to hit 3.26 in the next quarter and is forecasted to reach 14.25 in one year’s time.
Technical Analysis of Abbvie Inc (ABBV)
Abbvie Inc (NYSE: ABBV) saw its 5-day average volume 4.24 million, a negative change from its year-to-date volume of 6.79 million. As of the previous 9 days, the stock’s Stochastic %D was 81.47%.
During the past 100 days, Abbvie Inc’s (ABBV) raw stochastic average was set at 66.27%, which indicates a significant decrease from 85.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 4.34 in the past 14 days, which was lower than the 5.09 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $189.63, while its 200-day Moving Average is $188.03.
